These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 24401641)

  • 21. Beginning antiretroviral therapy for patients with HIV.
    Johnson JA; Sax PE
    Infect Dis Clin North Am; 2014 Sep; 28(3):421-38. PubMed ID: 25151564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study.
    Kovari H; Sabin CA; Ledergerber B; Ryom L; Worm SW; Smith C; Phillips A; Reiss P; Fontas E; Petoumenos K; De Wit S; Morlat P; Lundgren JD; Weber R
    Clin Infect Dis; 2013 Mar; 56(6):870-9. PubMed ID: 23090925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between atazanavir plasma levels and renal function in HIV-positive individuals on antiretroviral therapy with undetectable viral load.
    Luz AJ; Poeta J; Linden R; Antunes MV; Caminha LI; Callegari-Jacques SM; Sprinz E
    Int J Antimicrob Agents; 2013 May; 41(5):497-8. PubMed ID: 23453620
    [No Abstract]   [Full Text] [Related]  

  • 24. Raltegravir-based highly active antiretroviral therapy has beneficial effects on the renal function of human immunodeficiency virus-infected patients after solid organ transplantation.
    Moreno A; Pérez-Elías MJ; Casado JL; Fortún J; Bárcena R; Quereda C; Del Campo S; Gutiérrez C; Pastor O; Nuño J; Fernandez A; Moreno S
    Liver Transpl; 2010 Apr; 16(4):530-2. PubMed ID: 20213666
    [No Abstract]   [Full Text] [Related]  

  • 25. HIV in 2010: potent antiretroviral drugs treat and sensitive assays monitor the infection; but there remain outstanding issues.
    Antonelli G
    Clin Microbiol Infect; 2010 Oct; 16(10):1509-10. PubMed ID: 20854461
    [No Abstract]   [Full Text] [Related]  

  • 26. Adverse interactions with antiretroviral agents: focus on recreational and addiction drugs.
    Vassilev ZP; Marcus SM
    AIDS Read; 2004 Feb; 14(2):96. PubMed ID: 15083804
    [No Abstract]   [Full Text] [Related]  

  • 27. Management of Virologic Failure and HIV Drug Resistance.
    McCluskey SM; Siedner MJ; Marconi VC
    Infect Dis Clin North Am; 2019 Sep; 33(3):707-742. PubMed ID: 31255384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term effectiveness and safety of third-line antiretroviral regimens among patients in Western India.
    Pujari SN; Makane A; Lodha A; Bele V; Joshi K
    J Acquir Immune Defic Syndr; 2014 Feb; 65(2):e82-4. PubMed ID: 24442229
    [No Abstract]   [Full Text] [Related]  

  • 29. 30 years after HIV identification: where to from here?
    Stover J
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):947-9. PubMed ID: 22029511
    [No Abstract]   [Full Text] [Related]  

  • 30. Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing.
    Pou C; Noguera-Julian M; Pérez-Álvarez S; García F; Delgado R; Dalmau D; Álvarez-Tejado M; Gonzalez D; Sayada C; Chueca N; Pulido F; Ibáñez L; Rodríguez C; Casadellà M; Santos JR; Ruiz L; Clotet B; Paredes R
    Clin Infect Dis; 2014 Aug; 59(4):578-88. PubMed ID: 24879788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antiretroviral therapy in 2004].
    Jablonowski H
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():46-8, 50-1. PubMed ID: 15373049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continued correspondence 'Will ART rollout in Africa drive an epidemic of drug-resistant HIV?'.
    Hastings IM; Lalloo DG; Khoo SH
    AIDS; 2007 Jan; 21(2):258-9; author reply 259-60. PubMed ID: 17197825
    [No Abstract]   [Full Text] [Related]  

  • 33. Twenty years of boosting antiretroviral agents: where are we today?
    Boffito M; Back D; Gatell JM
    AIDS; 2015 Nov; 29(17):2229-33. PubMed ID: 26544697
    [No Abstract]   [Full Text] [Related]  

  • 34. Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management.
    Fernandez-Montero JV; Eugenia E; Barreiro P; Labarga P; Soriano V
    Expert Opin Drug Saf; 2013 Sep; 12(5):697-707. PubMed ID: 23730950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structured interruptions of therapy: looking for the best protocol.
    Aiuti F; Giovannetti A
    AIDS; 2003 Oct; 17(15):2257-8. PubMed ID: 14523284
    [No Abstract]   [Full Text] [Related]  

  • 36. HIV and drug resistance - interpretation and therapeutic progress.
    Gürtler L
    Intervirology; 2012; 55(2):77-8. PubMed ID: 22286873
    [No Abstract]   [Full Text] [Related]  

  • 37. Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
    Grinspoon S; Carr A
    N Engl J Med; 2005 Jan; 352(1):48-62. PubMed ID: 15635112
    [No Abstract]   [Full Text] [Related]  

  • 38. Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions.
    Soriano V; Rivas P; Nuñez M
    Clin Infect Dis; 2008 Dec; 47(11):1486-9. PubMed ID: 18937578
    [No Abstract]   [Full Text] [Related]  

  • 39. Highlights on HIV eradication in 2013.
    Monforte Ad; Svicher V; Nozza S; Lazzarin A; Marchetti G; Perno CF
    AIDS; 2014 Jan; 28(1):1-7. PubMed ID: 23939240
    [No Abstract]   [Full Text] [Related]  

  • 40. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia.
    Aghokeng AF; Monleau M; Eymard-Duvernay S; Dagnra A; Kania D; Ngo-Giang-Huong N; Toni TD; Touré-Kane C; Truong LX; Delaporte E; Chaix ML; Peeters M; Ayouba A;
    Clin Infect Dis; 2014 Jan; 58(1):99-109. PubMed ID: 24076968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.